Equities analysts expect Agilent Technologies, Inc. (NYSE:A) to post $1.16 billion in sales for the current fiscal quarter, Zacks reports. Seven analysts have issued estimates for Agilent Technologies’ earnings, with the highest sales estimate coming in at $1.17 billion and the lowest estimate coming in at $1.15 billion. Agilent Technologies posted sales of $1.07 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 8.4%. The firm is scheduled to issue its next earnings report on Tuesday, February 13th.
On average, analysts expect that Agilent Technologies will report full year sales of $1.16 billion for the current year, with estimates ranging from $4.74 billion to $4.79 billion. For the next financial year, analysts anticipate that the company will post sales of $5.02 billion per share, with estimates ranging from $4.98 billion to $5.10 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Agilent Technologies.
Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Monday, November 20th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. Agilent Technologies had a net margin of 15.30% and a return on equity of 16.96%. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the previous year, the company posted $0.59 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year.
Agilent Technologies (NYSE A) opened at $68.69 on Monday. Agilent Technologies has a 1-year low of $43.27 and a 1-year high of $70.93. The stock has a market cap of $22,106.37, a price-to-earnings ratio of 28.98, a PEG ratio of 2.08 and a beta of 1.27. The company has a current ratio of 3.30, a quick ratio of 2.85 and a debt-to-equity ratio of 0.37.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Shareholders of record on Tuesday, January 2nd will be given a $0.149 dividend. The ex-dividend date of this dividend is Friday, December 29th. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. This represents a $0.60 annualized dividend and a yield of 0.87%. Agilent Technologies’s payout ratio is 25.24%.
In other Agilent Technologies news, insider Patrick Kaltenbach sold 5,000 shares of the business’s stock in a transaction dated Friday, September 8th. The shares were sold at an average price of $65.26, for a total value of $326,300.00. Following the sale, the insider now directly owns 45,143 shares in the company, valued at $2,946,032.18. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Didier Hirsch sold 1,200 shares of the business’s stock in a transaction dated Wednesday, September 13th. The stock was sold at an average price of $66.00, for a total transaction of $79,200.00. Following the completion of the sale, the chief financial officer now owns 164,202 shares in the company, valued at $10,837,332. The disclosure for this sale can be found here. Over the last quarter, insiders sold 151,114 shares of company stock worth $10,359,388.
A number of hedge funds and other institutional investors have recently bought and sold shares of A. Dupont Capital Management Corp acquired a new stake in Agilent Technologies during the 3rd quarter worth about $101,000. Balentine LLC raised its holdings in Agilent Technologies by 2.9% during the 2nd quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock worth $106,000 after buying an additional 50 shares during the period. Sun Life Financial INC raised its holdings in Agilent Technologies by 26,144.4% during the 2nd quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock worth $140,000 after buying an additional 2,353 shares during the period. Acrospire Investment Management LLC raised its holdings in Agilent Technologies by 92.3% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock worth $148,000 after buying an additional 1,200 shares during the period. Finally, Parallel Advisors LLC raised its holdings in Agilent Technologies by 5.3% during the 2nd quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock worth $157,000 after buying an additional 131 shares during the period.
COPYRIGHT VIOLATION NOTICE: “Brokerages Expect Agilent Technologies, Inc. (A) Will Post Quarterly Sales of $1.16 Billion” was published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://www.com-unik.info/2017/12/04/brokerages-expect-agilent-technologies-inc-a-will-post-quarterly-sales-of-1-16-billion.html.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Agilent Technologies Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Agilent Technologies Inc. and related companies.